News & Events
News & Events
Institut Pasteur Korea Strengthens Collaboration with Kyungpook National University Hospital and Kyungpook National University School of Medicine on Infectious Disease Research and Research Resource Sharing
2025-06-24
Institut Pasteur Korea Strengthens Collaboration with
Kyungpook National University Hospital and
Kyungpook National University School of Medicine on Infectious Disease Research and Research Resource Sharing
- Joint Research on Therapeutics and Vaccines, and Sharing of
- Joint Research on Therapeutics and Vaccines, and Sharing of
Infectious Disease Specimens and Pathogen Resources -
.jpg)
Logos from left to right: Institut Pasteur Korea, Kyungpook National University Hospital, Kyungpook National University School of Medicine.
(June, 24, 2025, Gyeonggi-do, Rep. of Korea) Institut Pasteur Korea (IPK) signed a Memorandum of Understanding (MoU) with Kyungpook National University Hospital and the Kyungpook National University School of Medicine to enhance collaborative research on infectious diseases.
The agreement aims to establish a collaborative research platform for conducting joint research, securing and analyzing clinical specimens and pathogens, and promoting effective use of research resources. Through strengthened cooperation with clinical institutions, the collaboration is expected to enhance the practical impact of infectious disease and antimicrobial resistance research.
Under this MoU, the three institutions will pursue joint efforts to develop vaccines and therapeutics against emerging and re-emerging infectious diseases. They also plan to explore research collaborations on antimicrobial resistance (AMR), while promoting the sharing of human-derived clinical specimens and pathogens, along with cooperative analysis of their characteristics.
As part of its broader mission, IPK continues to prioritize the establishment of a robust infectious disease research infrastructure In November 2023, the institute launched a network council involving nine partner institutions—including university hospitals—to build a collaborative network for the collection and sharing of infectious disease specimens and pathogens.
Sung Key Jang, CEO of Institut Pasteur Korea, stated, “By strengthening collaboration with clinical partners, we aim to accelerate the development of vaccines and therapeutics against new infectious diseases while promoting open access to research resources. These efforts will contribute to advancing the healthcare industry and improving public health outcomes.”
(June, 24, 2025, Gyeonggi-do, Rep. of Korea) Institut Pasteur Korea (IPK) signed a Memorandum of Understanding (MoU) with Kyungpook National University Hospital and the Kyungpook National University School of Medicine to enhance collaborative research on infectious diseases.
The agreement aims to establish a collaborative research platform for conducting joint research, securing and analyzing clinical specimens and pathogens, and promoting effective use of research resources. Through strengthened cooperation with clinical institutions, the collaboration is expected to enhance the practical impact of infectious disease and antimicrobial resistance research.
Under this MoU, the three institutions will pursue joint efforts to develop vaccines and therapeutics against emerging and re-emerging infectious diseases. They also plan to explore research collaborations on antimicrobial resistance (AMR), while promoting the sharing of human-derived clinical specimens and pathogens, along with cooperative analysis of their characteristics.
As part of its broader mission, IPK continues to prioritize the establishment of a robust infectious disease research infrastructure In November 2023, the institute launched a network council involving nine partner institutions—including university hospitals—to build a collaborative network for the collection and sharing of infectious disease specimens and pathogens.
Sung Key Jang, CEO of Institut Pasteur Korea, stated, “By strengthening collaboration with clinical partners, we aim to accelerate the development of vaccines and therapeutics against new infectious diseases while promoting open access to research resources. These efforts will contribute to advancing the healthcare industry and improving public health outcomes.”